Back to Top Skip to main content

Health.mil: the official website of the Military Health System (MHS) and the Defense Health Agency (DHA)

Utility Navigation Links

TRICARE Policy Manual 6010.60-M, April 1, 2015
Chapter 4
Section 9.1
Cardiovascular System
Issue Date:  August 26, 1985
Authority:  32 CFR 199.4(c)(2) and (c)(3)
Copyright:  CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.
Revision:  C-46, April 30, 2019
1.0  CPT PROCEDURE CODES
33010 - 33130, 33140, 33141, 33200 - 37186, 37195 - 37785, 92950 - 93272, 93303 - 93581, 93600 - 93745, 93770, 93797 - 93799, 0075T, 0076T, 0451T-0463T, 0151T - 0522T
2.0  DESCRIPTION
The cardiovascular system involves the heart and blood vessels, by which blood is pumped and circulated through the body.
3.0  POLICY
3.1  Medically necessary services and supplies required in the diagnosis and treatment of illness or injury involving the cardiovascular system are covered.
3.2  Ventricular Assist Devices (VADs).
3.2.1  VADs (external and implantable) are covered if the device is U.S. Food and Drug Administration (FDA) approved and used in accordance with FDA approved indications.
3.2.2  VADs as destination therapy (Current Procedural Terminology (CPT) procedure codes 33979, 0451T-0463T) are covered if they have received approval from the FDA for that purpose and are used according to the FDA approved labeling instructions. Benefits are authorized when the procedure is performed at a TRICARE-certified heart transplantation center, a TRICARE-certified pediatric consortium heart transplantation center, or a Medicare facility which is approved for VAD implantation as destination therapy, for patients who meet all of the following conditions:
3.2.2.1  The patient has chronic end-stage heart failure (New York Heart Association Class IV end-stage left ventricular failure for at least 90 days with a life expectancy of less than two years).
3.2.2.2  The patient is not a candidate for heart transplantation.
3.2.2.3  The patient’s Class IV heart failure symptoms have failed to respond to optimal medical management, including a dietary salt restriction, diuretics, digitalis, beta-blockers, and ACE inhibitors (if tolerated) for at least 60 of the last 90 days.
3.2.2.4  The patient has Left Ventricular Ejection Fraction (LVEF) less than 25%.
3.2.2.5  The patient has demonstrated functional limitation with a peak oxygen consumption of less than 12 ml/kg/min; or the patient has a continued need for intravenous inotropic therapy owing to symptomatic hypotension, decreasing renal function, or worsening pulmonary congestion.
3.2.2.6  The patient has the appropriate body size (by device per FDA labeling) to support the VAD implantation.
3.3  Gamma and beta intracoronary radiotherapy (brachytherapy) is covered for the treatment of in-stent restenosis in native coronary arteries.
3.4  Transmyocardial Revascularization (TMR) (CPT procedures codes 33140 and 33141).
3.4.1  Coverage is available for patients with stable class III or IV angina which has been found refractory to standard medical therapy, including drug therapy at the maximum tolerated or maximum safe dosages. In addition, the angina symptoms must be caused by areas of the heart not amenable to surgical therapies such as percutaneous transluminal coronary angioplasty, stenting, coronary atherectomy or coronary bypass.
3.4.2  Coverage is limited to those uses of the laser used in performing the procedure which have been approved by the FDA for the purpose for which they are being used.
3.5  TMR as an adjunct to Coronary Artery Bypass Graft (CABG) is covered for patients with documented areas of the myocardium that are not amenable to surgical revascularization due to unsuitable anatomy.
3.6  FDA approved IDE clinical trials. See Chapter 8, Section 5.1, paragraphs 2.5 and 2.6 for policy.
3.7  Endovenous Radiofrequency Ablation (RFA)/obliteration (CPT procedure codes 36475 and 36476) and endovenous laser ablation/therapy (CPT procedure codes 36478 and 36479) for the treatment of saphenous venous reflux of named saphenous veins (which include greater, small, anterior accessory and posterior accessory) with symptomatic varicose veins and/or incompetent perforator veins is covered when:
3.7.1  One of the following indications is present:
3.7.1.1  Persistent symptoms interfering with activities of daily living in spite of conservative/non-surgical management. Symptoms include aching, cramping, burning, itching and/or swelling during activity or after prolonged standing.
3.7.1.2  Significant recurrent attacks of superficial phlebitis.
3.7.1.3  Hemorrhage from a ruptured varix.
3.7.1.4  Ulceration from venous stasis where incompetent varices are a contributing factor.
3.7.2  A trial of conservative, non-operative treatment has failed. This would include mild exercise, avoidance of prolonged immobility, periodic elevation of legs, and compressive stockings.
3.7.3  The patient’s anatomy is amenable to endovenous ablation.
3.8  Ambulatory Blood Pressure Monitoring (ABPM) is only covered for beneficiaries with suspected white coat hypertension and is NOT covered for any other uses. The information obtained by ABPM is necessary in order to determine the appropriate medical management of the beneficiary. Suspected white coat hypertension is considered to exist when the following is documented:
3.8.1  There is no evidence of end-organ damage;
3.8.2  Office blood pressure greater than 140/90 mm Hg on at least three separate clinic/office visits with two separate measurements made at each visit; and
3.8.3  At least two blood pressure measurements taken outside the office which are less than 140/90 mm Hg.
3.9  Pulmonary vein isolation/ablation (CPT procedure code 93651) is covered for beneficiaries who meet the guidelines published in the Heart Rhythm Society (HRS)/European Heart Rhythm Association (EHRA)/European Cardiac Arrhythmia Society (ECAS) 2007 Consensus Statement as follows:
3.9.1  Symptomatic Atrial Fibrillation (AF) refractory or intolerant to at least one Class 1 or 3 antiarrhythmic medication.
3.9.2  In rare clinical situations, as first line therapy.
3.9.3  Selected symptomatic patients with heart failure and/or reduced ejection fraction.
3.9.4  The presence of a Left Atrial (LA) thrombus is a contraindication.
3.10  Primary percutaneous transluminal mechanical thrombectomy (CPT procedure codes 37184 and 37185) and secondary percutaneous transluminal mechanical thrombectomy (CPT procedure code 37186) are proven and are covered for the treatment of acute limb ischemia due to peripheral arterial occlusion.
3.11  Percutaneous Transluminal Angioplasty (PTA) of the carotid artery with stenting (CPT procedure codes 37215, 0075T, and 0076T) in beneficiaries at high risk for Carotid Endarterectomy (CEA) is proven and covered when all of the following criteria are met:
3.11.1  Beneficiaries who have symptomatic Carotid Artery Stenosis (CAS) greater than 70%.
3.11.2  Beneficiaries are at high risk for CEA due to one or more of the following significant comorbidities and/or anatomic risk factors:
•  Congestive heart failure (New York Heart Association Class I, II/IV).
•  Left ventricular ejection fraction of less than 30%.
•  Myocardial Infarction (MI) within past 30 days.
•  Unstable Angina.
•  Known severe Coronary Artery Disease (CAD).
•  Severe Chronic Obstructive Pulmonary Disease (COPD).
•  Contralateral carotid artery occlusion.
•  Contralateral laryngeal nerve palsy.
•  Previous radiation therapy to the neck.
•  Previous radical neck dissection.
•  Previous ipsilateral endarterectomy with restenosis.
•  Surgically inaccessible lesion.
•  Inability to move the neck to a suitable position for surgery.
•  Tracheostomy.
•  Coagulopathy or other coagulation issues leading to contraindication for endarterectomy.
3.11.3  Beneficiaries who have had a disabling stroke are excluded from coverage.
3.11.4  Coverage is limited to procedures performed using FDA approved carotid artery stents and embolic protection devices.
3.11.5  The use of a distal embolic protection device is required. If deployment of the distal embolic protection device is not technically possible, then the procedure should be aborted due to the risks of CAS without distal embolic protection.
3.11.6  The degree of CAS shall be measured by duplex Doppler ultrasound or carotid artery angiography and recorded in the beneficiary’s medical records. If the stenosis is measured by ultrasound prior to the procedure, then the degree of stenosis must be confirmed by angiography at the start of the procedure. If the stenosis is determined to be less than 70% by angiography, then CAS should not proceed.
3.11.7  All procedures are performed in a Centers for Medicare and Medicaid Services (CMS) approved facility that has been determined to be competent in performing the evaluation, procedure, and follow-up necessary to ensure optimal patient outcomes.
3.12  Transcatheter Aortic Valve Replacement (TAVR) for the treatment of severe symptomatic aortic stenosis is proven safe and effective for patients who are not candidates for Surgical Aortic Valve Replacement (SAVR).
3.13  Percutaneous transluminal mechanical thrombectomy (CPT procedure codes 37184, 37185, 37186) with stent retrievers for the treatment of adults with acute ischemic stroke is proven safe and effective.
3.14  TAVR for the treatment of severe symptomatic aortic stenosis in high-risk operative patients is considered proven safe and effective.
3.15  Intracranial angioplasty with stenting (CPT procedure code 61635) of the venous sinuses may be considered for cost-sharing for the treatment of pseudotumor cerebri (also known as idiopathic intracranial hypertension and benign intracranial hypertension).
3.16  Cardiography: electrocardiograms, rhythm strips, stress testing; Cardiovascular Monitoring: continuous ambulatory monitors (e.g., Holter monitor, Zio Patch), mobile cardiac telemetry, and event monitors; Implantable and Wearable Cardiac Devices: pacemakers, defibrillators, and loop recorders are covered when approved by the FDA and in accordance with Chapter 8, Section 5.1.
3.17  Left Atrial Appendage (LAA) closure for the prevention of embolism in patients with non-valvular atrial fibrillation is covered when performed with an FDA approved device used according to labeled specifications (e.g., WATCHMAN™ device).
3.18  Minimally Invasive Direct Coronary Artery Bypass (MIDCAB) is covered when medically necessary and appropriate.
3.19  Insertion, evaluation, replacement, and removal of wireless cardiac stimulator for pacing of the lower left chamber of the heart (CPT codes 0515T-0522T) is covered for use with WiSE-CRT system (in accordance with the FDA-approved investigational device exemption policy, Chapter 8, Section 5.1).
4.0  EXCLUSIONS
4.1  Thermogram; cephalic (CPT procedure code 93760); peripheral (CPT procedure code 93762) are unproven.
4.2  Percutaneous Myocardial Laser Revascularization (PMR) is unproven.
4.3  Cardiomyoplasty (Cardiac Wrap) for treatment of heart failure is unproven.
4.4  Port Access Coronary Artery Bypass (PACAB) is unproven.
4.5  Percutaneous Transluminal Angioplasty (PTA) in the treatment of obstructive lesions of the vertebral and cerebral arteries is unproven. PTA of the carotid artery without stenting is unproven. PTA of the carotid artery with stenting but without embolic protection (CPT procedure code 37216) is unproven.
4.6  Signal-Average Electrocardiography (CPT procedure code 93278) is unproven.
4.7  Percutaneous transluminal mechanical thrombectomy vein(s) including intraprocedural pharmacological thrombolytic injections and fluroscopic guidance (CPT procedure code 37187) is unproven.
4.8  Percutaneous transluminal mechanical thrombectomy, vein(s) including intraprocedural pharmacological thrombolytic injections and fluroscopic guidance, repeat treatment on subsequent day during course of thrombolytic therapy (CPT procedure code 37188) is unproven.
4.9  LAA closure using the LARIAT® Suture Delivery Device is excluded as the LARIAT® device fails to meet the off-label device requirements in Chapter 8, Section 5.1.
5.0  EFFECTIVE DATES
5.1  March 1, 2001, for gamma and beta intracoronary radiotherapy (brachytherapy).
5.2  January 1, 2002, for TMR.
5.3  October 1, 2003, for VADs as destination therapy.
5.4  December 1, 2003, for endovenous RFA/obliteration.
5.5  January 1, 2005, for ABPM.
5.6  March 17, 2005, for PTA of the carotid artery with stenting in beneficiaries at high risk for CEA.
5.7  March 21, 2006, for percutaneous transluminal mechanical thrombectomy for acute limb ischemia.
5.8  January 1, 2007, for pulmonary vein isolation/ablation.
5.9  January 1, 2009, for endovenous laser ablation/therapy.
5.10  May 1, 2011, for endovenous RFA/obliteration for the treatment of incompetent perforator veins.
5.11  July 27, 2012, for endovenous laser ablation/therapy for the treatment of incompetent perforator veins.
5.12  February 8, 2012, for TAVR for the treatment of severe symptomatic aortic stenosis in patients who are not candidates for SAVR.
5.13  July 27, 2012, for TAVR, for treatment of severe symptomatic aortic stenosis in high-risk operative patients.
5.14  June 25, 2014, for intracranial angioplasty with stenting of the venous sinuses for the treatment of pseudotumor cerebri.
5.15  November 30, 2014, for continuous ambulatory Electrocardiogram (ECG) recording greater than 48 hours.
5.16  January 7, 2015, for percutaneous transluminal mechanical thrombectomy with stent retrievers.
5.17  July 2, 2015, for LAA closure for the prevention of embolism in patients with non-valvular atrial fibrillation.
5.18  January 1, 2017, for VADs (CPT procedure codes 0451T-0463T).
5.19  December 29, 2011, for MIDCAB.
- END -

Utility Navigation Links

DoD Seal

tricare.mil is the official website of the Defense Health Agency (DHA) a component of the Military Health System

TRICARE is a registered trademark of the Department of Defense (DoD), DHA. All rights reserved.

CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

If you have a question regarding TRICARE benefits, please go to the TRICARE Contact Us page page.
If you need help with technical/operational issues, please go to the TRICARE Manuals Online Frequently Asked Questions page.

The appearance of hyperlinks to external websites does not constitute endorsement by the DHA of these websites or the information, products or services contained therein. For other than authorized government activities, the DHA does not exercise any editorial control over the information you may find at other locations. Such links are provided consistent with the stated purpose of this DoD website.

v4.8.7983.18738

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.